GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » Debt-to-EBITDA

WuXi XDC Cayman (HKSE:02268) Debt-to-EBITDA : 0.38 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

WuXi XDC Cayman's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$514 Mil. WuXi XDC Cayman's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was HK$16 Mil. WuXi XDC Cayman's annualized EBITDA for the quarter that ended in Dec. 2024 was HK$1,412 Mil. WuXi XDC Cayman's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.38.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for WuXi XDC Cayman's Debt-to-EBITDA or its related term are showing as below:

HKSE:02268' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01   Med: 0.31   Max: 0.4
Current: 0.4

During the past 5 years, the highest Debt-to-EBITDA Ratio of WuXi XDC Cayman was 0.40. The lowest was 0.01. And the median was 0.31.

HKSE:02268's Debt-to-EBITDA is ranked better than
81.48% of 108 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.635 vs HKSE:02268: 0.40

WuXi XDC Cayman Debt-to-EBITDA Historical Data

The historical data trend for WuXi XDC Cayman's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Debt-to-EBITDA Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
- 0.29 0.34 0.01 0.37

WuXi XDC Cayman Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial 0.41 0.01 0.01 0.06 0.38

Competitive Comparison of WuXi XDC Cayman's Debt-to-EBITDA

For the Diagnostics & Research subindustry, WuXi XDC Cayman's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi XDC Cayman's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where WuXi XDC Cayman's Debt-to-EBITDA falls into.


;
;

WuXi XDC Cayman Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

WuXi XDC Cayman's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(513.844 + 16.175) / 1423.617
=0.37

WuXi XDC Cayman's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(513.844 + 16.175) / 1411.528
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2024) EBITDA data.

WuXi XDC Cayman  (HKSE:02268) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

WuXi XDC Cayman Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi XDC Cayman Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » Debt-to-EBITDA
Comparable Companies
HKSE:09860 HKSE:02325 HKSE:06667 HKSE:09960 HKSE:08037 HKSE:02427 HKSE:08225 HKSE:08247 HKSE:00928 TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA WAT DGX
Traded in Other Exchanges
L74:Germany
Address
No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
Website
https://www.wuxixdc.com
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.
Executives
Shang Hai He Quan Yao Ye Gu Fen You Xian Gong Si
He Quan Yao Ye Xiang Gang Tou Zi You Xian Gong Si
Shang Hai Yao Ming Kang De Xin Yao Kai Fa You Xian Gong Si
Wu Xi Yao Ming Kang De Xin Yao Kai Fa Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Morgan Stanley 2201 Interest of corporation controlled by you
Wuxi Biologics (cayman) Inc. 2101 Beneficial owner
Wuxi Apptec Co., Ltd.

WuXi XDC Cayman Headlines

No Headlines